Skip to main content

Table 1 Characteristics of patients at study entry and stratified by CKD stages at the follow-up clinical visits. Chronic Renal Insufficiency Cohort Study, United States, 2003-2019

From: Predicting the risk of a clinical event using longitudinal data: the generalized landmark analysis

 

All Follow-up

Baseline

CKD Stage 1-2

CKD Stage 3

CKD Stage 4-5

No. (%) Patients

3939 (100%)

3939 (100%)

1028 (15.0%)

3168 (66.5%)

1917 (18.5%)

No. Visits

28638

3939

4904

17388

6346

eGFRa

43.9 (17.0)

44.3 (15.0)

70.5 (9.36)

44.4 (8.33)

22.2 (5.57)

log UP/CR a

-1.63 (1.48)

-1.49 (1.64)

-2.39 (1.05)

-1.81 (1.35)

-0.54 (1.50)

Age a

62.7 (11.0)

57.7 (11.0)

57.4 (11.2)

63.9 (10.4)

63.4 (11.3)

Age b

62.7 (11.0)

57.7 (11.0)

55.5 (11.6)

58.7 (10.5)

60.8 (11.4)

Sex b

     

   Female

1778 (45.1%)

1778 (45.1%)

452 (44.0%)

1407 (44.4%)

861 (44.9%)

   Male

2161 (54.9%)

2161 (54.9%)

576 (56.0%)

1761 (55.6%)

1056 (55.1%)

Age groups b

     

    < 40

317 (8.05%)

317 (8.05%)

119 (11.6%)

203 (6.41%)

106 (5.53%)

   [40,50)

493 (12.5%)

493 (12.5%)

159 (15.5%)

347 (11.0%)

206 (10.7%)

   [50,60)

1169 (29.7%)

1169 (29.7%)

326 (31.7%)

900 (28.4%)

458 (23.9%)

   [60,70)

1433 (36.4%)

1433 (36.4%)

326 (31.7%)

1257 (39.7%)

679 (35.4%)

    \(\geqslant 70\)

527 (13.4%)

527 (13.4%)

98 (9.53%)

461 (14.6%)

468 (24.4%)

Time to event c

11.3 (3.80)

8.84 (4.85)

12.9 (2.37)

11.7 (3.48)

8.61 (4.22)

  1. a Numbers are summarized at the clinical visit level.
  2. b Numbers are summarized at the patient level. For Age, the values are based on the first encounter in each cohort.
  3. c This is the mean (standard deviation) of residual follow-up in years since each clinic visit